A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer
Phase 2
18 Years
N/A
18 Years
N/A
Not Enrolling
Male
Prostatic Neoplasms, Neoplasm Metastasis, Palliative Care
Male
Prostatic Neoplasms, Neoplasm Metastasis, Palliative Care
Trial Information
A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer
Inclusion Criteria:
- diagnosis of prostate cancer
- receiving docetaxel-based chemotherapy at the CCI
- age 18 years or over
- approval of oncologist
- informed written consent
Exclusion Criteria:
- life expectancy less than 6 months
- Karnofsky performance score less than 70
- contraindications for exercise (e.g. uncontrolled cardiac, respiratory, hypertensive
or psychiatric disorder)
- unable to understand, read, write and speak English
- unable or unwilling to attend supervised exercise sessions 3 times weekly
- unable or unwilling to complete outcome assessments
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
feasibility (recruitment, adherence, safety)
Principal Investigator
Kerry Courneya, M.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
Cross Cancer Institute
Authority:
Canada: Health Canada
Study ID:
SP-14-0049 / 22262
NCT ID:
NCT00271687
Start Date:
February 2006
Completion Date:
November 2007
Related Keywords:
- Prostatic Neoplasms
- Neoplasm Metastasis
- Palliative Care
- exercise
- exercise therapy
- activities of daily living
- quality of life
- Neoplasms
- Neoplasm Metastasis
- Prostatic Neoplasms
Name | Location |
|---|
